antipyrine has been researched along with Biliary Cirrhosis in 8 studies
Antipyrine: An analgesic and antipyretic that has been given by mouth and as ear drops. Antipyrine is often used in testing the effects of other drugs or diseases on drug-metabolizing enzymes in the liver. (From Martindale, The Extra Pharmacopoeia, 30th ed, p29)
antipyrine : A pyrazolone derivative that is 1,2-dihydropyrazol-3-one substituted with methyl groups at N-1 and C-5 and with a phenyl group at N-2.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The metabolism of antipyrine to each of its three major metabolites 4-hydroxy-, 3-methylhydroxy- and norantipyrine has previously been demonstrated to be differentially affected in alcoholic cirrhosis." | 7.68 | Antipyrine elimination in patients with alcoholic and non-alcoholic cirrhosis. ( Heidemann, HT; Hoffmann, K; Wensing, G, 1993) |
| "Nine patients with primary biliary cirrhosis received 300-450 mg/day of rifampin and placebo sequentially, in random order." | 6.66 | Treatment of pruritus in primary biliary cirrhosis with rifampin. Results of a double-blind, crossover, randomized trial. ( Carruthers, SG; Ghent, CN, 1988) |
| " When compared to patients in stage I, patients in advanced stages showed a reduction in antipyrine clearance (-29% and -44% in stages III and IV, respectively) and increases in antipyrine half-life (+24% and +75% in stages III and IV, respectively)." | 5.31 | Antipyrine clearance and metabolite formation in primary biliary cirrhosis. ( Almar, M; González-Gallego, J; Jorquera, F; Linares, A; Olcóz, JL; Rodrigo, L, 2001) |
| "Within the primary biliary cirrhosis group, there was no correlation between total bilirubin and clearance (r = ." | 5.29 | Antipyrine kinetics in patients with primary biliary cirrhosis. ( Abernethy, DR; Greenblatt, DJ; Kaplan, MM; von Moltke, LL, 1993) |
| " We investigated to what extent antipyrine clearance and metabolite formation are impaired in two models of liver cirrhosis in the rat, namely micronodular cirrhosis induced by chronic exposure to phenobarbital/CCl4 and biliary cirrhosis induced by bile duct ligation." | 3.68 | Metabolism of antipyrine in vivo in two rat models of liver cirrhosis. Its relationship to intrinsic clearance in vitro and microsomal membrane lipid composition. ( Buters, JT; Reichen, J; Zysset, T, 1993) |
| "The metabolism of antipyrine to each of its three major metabolites 4-hydroxy-, 3-methylhydroxy- and norantipyrine has previously been demonstrated to be differentially affected in alcoholic cirrhosis." | 3.68 | Antipyrine elimination in patients with alcoholic and non-alcoholic cirrhosis. ( Heidemann, HT; Hoffmann, K; Wensing, G, 1993) |
| "Medroxyprogesterone acetate (MPA) elimination rate was investigated in 25 patients with primary biliary cirrhosis, alcoholic cirrhosis and fatty liver." | 3.67 | Liver function and medroxyprogesterone acetate elimination in man. ( Rautio, A, 1984) |
| "Nine patients with primary biliary cirrhosis received 300-450 mg/day of rifampin and placebo sequentially, in random order." | 2.66 | Treatment of pruritus in primary biliary cirrhosis with rifampin. Results of a double-blind, crossover, randomized trial. ( Carruthers, SG; Ghent, CN, 1988) |
| " When compared to patients in stage I, patients in advanced stages showed a reduction in antipyrine clearance (-29% and -44% in stages III and IV, respectively) and increases in antipyrine half-life (+24% and +75% in stages III and IV, respectively)." | 1.31 | Antipyrine clearance and metabolite formation in primary biliary cirrhosis. ( Almar, M; González-Gallego, J; Jorquera, F; Linares, A; Olcóz, JL; Rodrigo, L, 2001) |
| "Within the primary biliary cirrhosis group, there was no correlation between total bilirubin and clearance (r = ." | 1.29 | Antipyrine kinetics in patients with primary biliary cirrhosis. ( Abernethy, DR; Greenblatt, DJ; Kaplan, MM; von Moltke, LL, 1993) |
| "Six patients with primary biliary cirrhosis (PBC) were treated with a daily oral dose of 600 mg rifampicin for 2 weeks to induce the hepatic metabolism of drugs and bile acids." | 1.27 | Effect of rifampicin treatment on hepatic drug metabolism and serum bile acids in patients with primary biliary cirrhosis. ( Balzer, K; Dylewizc, P; Goebell, H; Hoensch, HP; Kirch, W; Ohnhaus, EE, 1985) |
| "Antipyrine metabolism was normal or marginally impaired in patients with compensated cirrhosis or acute hepatitis, whereas it was frequently abnormal in those with chronic active hepatitis or advanced alcoholic liver disease." | 1.26 | Drug metabolism in liver disease. Identification of patients with impaired hepatic drug metabolism. ( Cooksley, WG; Farrell, GC; Hart, P; Powell, LW, 1978) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 4 (50.00) | 18.7374 |
| 1990's | 3 (37.50) | 18.2507 |
| 2000's | 1 (12.50) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Rautio, A | 1 |
| Buters, JT | 1 |
| Zysset, T | 1 |
| Reichen, J | 1 |
| von Moltke, LL | 1 |
| Abernethy, DR | 1 |
| Kaplan, MM | 1 |
| Greenblatt, DJ | 1 |
| Wensing, G | 1 |
| Hoffmann, K | 1 |
| Heidemann, HT | 1 |
| Jorquera, F | 1 |
| Almar, M | 1 |
| Linares, A | 1 |
| Olcóz, JL | 1 |
| Rodrigo, L | 1 |
| González-Gallego, J | 1 |
| Farrell, GC | 1 |
| Cooksley, WG | 1 |
| Hart, P | 1 |
| Powell, LW | 1 |
| Ghent, CN | 1 |
| Carruthers, SG | 1 |
| Hoensch, HP | 1 |
| Balzer, K | 1 |
| Dylewizc, P | 1 |
| Kirch, W | 1 |
| Goebell, H | 1 |
| Ohnhaus, EE | 1 |
1 trial available for antipyrine and Biliary Cirrhosis
| Article | Year |
|---|---|
Treatment of pruritus in primary biliary cirrhosis with rifampin. Results of a double-blind, crossover, randomized trial.
Topics: Antipyrine; Bile Acids and Salts; Clinical Trials as Topic; Double-Blind Method; Female; Humans; Liv | 1988 |
7 other studies available for antipyrine and Biliary Cirrhosis
| Article | Year |
|---|---|
Liver function and medroxyprogesterone acetate elimination in man.
Topics: Antipyrine; Fatty Liver; Female; Humans; Liver; Liver Cirrhosis, Alcoholic; Liver Cirrhosis, Biliary | 1984 |
Metabolism of antipyrine in vivo in two rat models of liver cirrhosis. Its relationship to intrinsic clearance in vitro and microsomal membrane lipid composition.
Topics: Animals; Antipyrine; Bile Acids and Salts; Breath Tests; Carbon Tetrachloride; Lipids; Liver Cirrhos | 1993 |
Antipyrine kinetics in patients with primary biliary cirrhosis.
Topics: Adult; Aged; Antipyrine; Bilirubin; Female; Half-Life; Humans; Infusions, Intravenous; Liver Cirrhos | 1993 |
Antipyrine elimination in patients with alcoholic and non-alcoholic cirrhosis.
Topics: Adult; Antipyrine; Female; Humans; Liver Cirrhosis; Liver Cirrhosis, Alcoholic; Liver Cirrhosis, Bil | 1993 |
Antipyrine clearance and metabolite formation in primary biliary cirrhosis.
Topics: Adult; Aged; Aged, 80 and over; Antipyrine; Bilirubin; Biopsy; Case-Control Studies; Female; Humans; | 2001 |
Drug metabolism in liver disease. Identification of patients with impaired hepatic drug metabolism.
Topics: Acute Disease; Antipyrine; Ascites; Biotransformation; Chemical and Drug Induced Liver Injury; Chole | 1978 |
Effect of rifampicin treatment on hepatic drug metabolism and serum bile acids in patients with primary biliary cirrhosis.
Topics: Adult; Alkaline Phosphatase; Antipyrine; Bile Acids and Salts; Humans; Liver; Liver Cirrhosis, Bilia | 1985 |